Intimation of Investor Presentation under Regulation 30 of SEBI (LODR) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aptus Pharma has submitted its Investor Presentation to BSE for dissemination to investors and analysts, in compliance with SEBI LODR regulations. The company operates as a pharmaceutical marketing and distribution business using a contract manufacturing model, with a portfolio of 210+ products across 11+ therapeutic segments and 4 divisions (WellCare, CD Care, Pioneer, and Global exports). The presentation outlines its 'Vision 2026-30' which includes PAN India expansion, launching 450+ products across 25+ therapeutic segments, a franchise model in Odisha, entry into unregulated/semi-regulated global markets, and expansion into neighbour states within 3 years. Recent strategic moves highlighted include OTC expansion in Gujarat and entry into the fast-growing Indian urology segment (growing ~9-10% annually). The filing explicitly states the presentation contains no unpublished price-sensitive information.
This is a routine regulatory disclosure sharing publicly available information, so the immediate stock impact is likely neutral. However, the presentation provides investors with visibility into the company's multi-year growth roadmap, including aggressive product and geographic expansion plans, which could be a positive narrative for long-term investors.